Sub menu

 

 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset for information on the evaluation of prescription medicines.

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Sponsor

Topics

AusPAR Date

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

1143 result(s) found, displaying 251 to 275

  • AusPAR: Tepmetko

    Australian public assessment report (AusPar)
    Tepmetko (tepotinib) for treatment of non-small cell lung cancer with MET exon 14 skipping alterations.

  • AusPAR: Tecentriq

    Australian public assessment report (AusPar)
    New AusPAR for Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer.

  • AusPAR: Brukinsa

    Australian public assessment report (AusPar)
    Brukinsa (zanubrutinib) for the treatment of of adult patients with Waldenström’s macroglobulinaemia

  • AusPAR: Brukinsa

    Australian public assessment report (AusPar)
    Brukinsa (zanubrutinib) for the treatment of adult patients with mantle cell lymphoma

  • AusPAR: Nextstellis

    Australian public assessment report (AusPar)
    Nextstellis (estetrol monohydrate and drospirenone) for the prevention of pregnancy

  • AusPAR: Spikevax

    Australian public assessment report (AusPar)
    Spikevax (elasomeran) for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older

  • AusPAR: Tivicay and Tivicay PD

    Australian public assessment report (AusPar)
    TIVICAY (dolutegravir ) for treatment of HIV infection in combination with other antiretroviral agents.

  • AusPAR: Nuvaxovid

    Australian public assessment report (AusPar)
    Nuvaxovid (SARS-CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for prevention of COVID-19 in individuals 12 years of age and older.

  • AusPAR: Crysvita

    Australian public assessment report (AusPar)
    Crysvita (burosumab) for the treatment of X-linked hypophosphataemia (XLH)

  • AusPAR: Verquvo

    Australian public assessment report (AusPar)
    New AusPAR for Verquvo (vericiguat) as addition to standard of care therapy for the treatment of symptomatic chronic heart failure.

  • AusPAR: VeraSeal

    Australian public assessment report (AusPar)
    VeraSeal (human fibrinogen and human thrombin) for the supportive treatment of hemostasis.

  • AusPAR: Trastuzumab deruxtecan

    Australian public assessment report (AusPar)
    Enhertu (trastuzumab deruxtecan) for treatment of unresectable or metastatic HER2 positive breast cancer.

  • AusPAR: Nuvaxovid homologous booster

    Australian public assessment report (AusPar)
    Nuvaxovid homologous booster (CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for the prevention of COVID-19.

  • AusPAR: Nuvaxovid heterologous booster

    Australian public assessment report (AusPar)
    Nuvaxovid heterologous booster (CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for the prevention of COVID-19.

  • AusPAR: Bevacizumab

    Australian public assessment report (AusPar)
    Bevacip/Bevaciptin (bevacizumab) for the treatment of types of cancer.

  • AusPAR: Finerenone

    Australian public assessment report (AusPar)
    Kerendia (finerenone) for the treatment of progressive decline of kidney function in adults.

  • AusPAR: Deutetrabenazine

    Australian public assessment report (AusPar)
    AUSTEDO (deutetrabenazine) for the treatment of chorea associated with Huntington's disease and tardive dyskinesia in adult.

  • AusPAR: Remdesivir

    Australian public assessment report (AusPar)
    New AusPAR for VEKLURY (remdesivir ) for the treatment of coronavirus disease 2019 in paediatric and adult patients.

  • AusPAR: Belumosudil

    Australian public assessment report (AusPar)
    New AusPAR for Rholistiq (belumosudil) for the treatment of patients with chronic graft-versus-host disease aged 12 years and older.

  • AusPAR: Dupilumab

    Australian public assessment report (AusPar)
    New AusPAR for Dupixent (dupilumab) for the treatment of atopic dermatitis and chronic rhinosinusitis with nasal polyposis.

  • AusPAR: Lurbinectedin

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Lurbinectedin

  • AusPAR: Luspatercept

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Luspatercept

  • AusPAR: Venetoclax

    Australian public assessment report (AusPar)
    New AusPAR for Venclexta (venetoclax) for acute myeloid leukaemia indication, provisional to full registration.